These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Passive immunization against tumor necrosis factor-alpha impairs host defense during pneumococcal pneumonia in mice. van der Poll T; Keogh CV; Buurman WA; Lowry SF Am J Respir Crit Care Med; 1997 Feb; 155(2):603-8. PubMed ID: 9032201 [TBL] [Abstract][Full Text] [Related]
5. Nitric oxide exerts distinct effects in local and systemic infections with Streptococcus pneumoniae. Kerr AR; Wei XQ; Andrew PW; Mitchell TJ Microb Pathog; 2004 Jun; 36(6):303-10. PubMed ID: 15120156 [TBL] [Abstract][Full Text] [Related]
6. Bactericidal efficacy of ABI-0043, a novel rifamycin, in a murine pneumococcal pneumonia model. Lee SY; Tessier PR; Murphy CK; Nicolau DP J Antibiot (Tokyo); 2006 Dec; 59(12):804-7. PubMed ID: 17323649 [TBL] [Abstract][Full Text] [Related]
7. Activation of neutrophils and inhibition of the proinflammatory cytokine response by endogenous granulocyte colony-stimulating factor in murine pneumococcal pneumonia. Knapp S; Hareng L; Rijneveld AW; Bresser P; van der Zee JS; Florquin S; Hartung T; van der Poll T J Infect Dis; 2004 Apr; 189(8):1506-15. PubMed ID: 15073689 [TBL] [Abstract][Full Text] [Related]
8. Modulation of cytokines and chemokines, limited pulmonary vascular bed permeability, and prevention of septicemia and death with ceftriaxone and interleukin-10 in pneumococcal pneumonia. Wang E; Simard M; Ouellet N; Bergeron Y; Beauchamp D; Bergeron MG J Infect Dis; 2000 Oct; 182(4):1255-9. PubMed ID: 10979929 [TBL] [Abstract][Full Text] [Related]
9. [Streptococcus pneumoniae-induced pulmonary consolidation prevented with tumor necrosis factor alpha monoclonal antibody in mouse]. Cui X; Zhang R; Fu W Zhonghua Yi Xue Za Zhi; 1995 Jan; 75(1):19-21, 61. PubMed ID: 7600313 [TBL] [Abstract][Full Text] [Related]
10. Local activation of the tissue factor-factor VIIa pathway in patients with pneumonia and the effect of inhibition of this pathway in murine pneumococcal pneumonia. Rijneveld AW; Weijer S; Bresser P; Florquin S; Vlasuk GP; Rote WE; Spek CA; Reitsma PH; van der Zee JS; Levi M; van der Poll T Crit Care Med; 2006 Jun; 34(6):1725-30. PubMed ID: 16625114 [TBL] [Abstract][Full Text] [Related]
11. Anti-tumor necrosis factor-alpha therapy during murine Klebsiella pneumoniae bacteremia: increased mortality in the absence of liver injury. Moore TA; Lau HY; Cogen AL; Monteleon CL; Standiford TJ Shock; 2003 Oct; 20(4):309-15. PubMed ID: 14501943 [TBL] [Abstract][Full Text] [Related]
12. CD11b limits bacterial outgrowth and dissemination during murine pneumococcal pneumonia. Rijneveld AW; de Vos AF; Florquin S; Verbeek JS; van der Poll T J Infect Dis; 2005 May; 191(10):1755-60. PubMed ID: 15838804 [TBL] [Abstract][Full Text] [Related]
13. Interleukin-1 receptor antagonist transiently impairs antibacterial defense but not survival in murine pneumococcal pneumonia. Rijneveld AW; Florquin S; Speelman P; Edwards CK; Dinarello CA; van der Poll T Eur Cytokine Netw; 2003; 14(4):242-5. PubMed ID: 14715417 [TBL] [Abstract][Full Text] [Related]
14. Defective innate antibacterial host responses during murine Klebsiella pneumoniae bacteremia: tumor necrosis factor (TNF) receptor 1 deficiency versus therapy with anti-TNF-alpha. Moore TA; Lau HY; Cogen AL; Standiford TJ Clin Infect Dis; 2005 Aug; 41 Suppl 3():S213-7. PubMed ID: 15983903 [TBL] [Abstract][Full Text] [Related]
15. Recombinant activated protein C attenuates coagulopathy and inflammation when administered early in murine pneumococcal pneumonia. Schouten M; van 't Veer C; Roelofs JJ; Gerlitz B; Grinnell BW; Levi M; van der Poll T Thromb Haemost; 2011 Dec; 106(6):1189-96. PubMed ID: 21901240 [TBL] [Abstract][Full Text] [Related]
16. Experimental study of teicoplanin, alone and in combination, in the therapy of cephalosporin-resistant pneumococcal meningitis. Fernández A; Cabellos C; Tubau F; Maiques JM; Doménech A; Ribes S; Liñares J; Viladrich PF; Gudiol F J Antimicrob Chemother; 2005 Jan; 55(1):78-83. PubMed ID: 15546968 [TBL] [Abstract][Full Text] [Related]
17. The role of interferon-gamma in murine pneumococcal pneumonia. Rijneveld AW; Lauw FN; Schultz MJ; Florquin S; Te Velde AA; Speelman P; Van Deventer SJ; Van Der Poll T J Infect Dis; 2002 Jan; 185(1):91-7. PubMed ID: 11756986 [TBL] [Abstract][Full Text] [Related]
18. Effects of specific neutrophil elastase inhibitor, sivelestat sodium hydrate, in murine model of severe pneumococcal pneumonia. Yanagihara K; Fukuda Y; Seki M; Izumikawa K; Miyazaki Y; Hirakata Y; Tsukamoto K; Yamada Y; Kamhira S; Kohno S Exp Lung Res; 2007 Mar; 33(2):71-80. PubMed ID: 17454103 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of recombinant human granulocyte colony-stimulating factor in a murine model of pneumococcal pneumonia: effects of lung inflammation and timing of treatment. Dallaire F; Ouellet N; Simard M; Bergeron Y; Bergeron MG J Infect Dis; 2001 Jan; 183(1):70-7. PubMed ID: 11087202 [TBL] [Abstract][Full Text] [Related]
20. Therapeutic recombinant murine activated protein C attenuates pulmonary coagulopathy and improves survival in murine pneumococcal pneumonia. Schouten M; van 't Veer C; van den Boogaard FE; Gerlitz B; Grinnell BW; Roelofs JJ; Levi M; van der Poll T J Infect Dis; 2010 Nov; 202(10):1600-7. PubMed ID: 20925531 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]